Addressing the challenge of extended-spectrum beta-lactamases. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Current Opinion in Investigational Drugs Année : 2009

Addressing the challenge of extended-spectrum beta-lactamases.

Résumé

During the last decade, community-acquired extended-spectrum beta-lactamase (ESBL)-producing bacteria, and in particular Escherichia coli producing ESBLs of the CTX-M-type, have spread worldwide. These organisms are most often isolated from the urinary tract, but have also been isolated from bacteria in the blood. Cephalosporin- and fluoroquinolone-containing treatments are the two most common risk factors identified in patients with ESBL producers. In addition, associated resistance to other classes of antimicrobial agents are often observed in CTX-M producers, limiting the availability of therapeutic options. Carbapenems should be considered as the drug of choice for treating serious systemic infections caused by ESBL-producing bacteria, but preventing the spread of and appropriately managing these infections remains difficult.

Domaines

Bactériologie
Fichier non déposé

Dates et versions

hal-00464775 , version 1 (17-03-2010)

Identifiants

  • HAL Id : hal-00464775 , version 1
  • PUBMED : 19197795

Citer

Jean-Ralph Zahar, Olivier Lortholary, Claude Martin, Gilles Potel, Patrick Plesiat, et al.. Addressing the challenge of extended-spectrum beta-lactamases.. Current Opinion in Investigational Drugs, 2009, 10 (2), pp.172-80. ⟨hal-00464775⟩
179 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More